Current diagnosis and treatment of polymyositis and dermatomyositis

References

• Pinal-Fernandez I, Mammen AL. Spectrum of immune-mediated necrotizing myopathies and their treatments. Curr Opin Rheumatol. 2016;28:619–24.
   PubMed Web of Science ®Google Scholar
• Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol. 2012;24:602–8.
   PubMed Web of Science ®Google Scholar
• Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis. Lancet. 2003;362:971–82.
   PubMed Web of Science ®Google Scholar
• Hoogendijk JE, Amato AA, Lecky BR, Choy EH, Lundberg IE, Rose MR, et al. 119th ENMC International Workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, the Netherlands. Neuromuscul Disord. 2004;14:337–45.
   PubMedGoogle Scholar
• Targoff IN, Miller FW, Medsger TA, Jr., Oddis CV. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1997;9:527–35.
   PubMedGoogle Scholar
• van der Meulen MF, Bronner IM, Hoogendijk JE, Burger H, van Venrooij WJ, Voskuyl AE, et al. Polymyositis: an overdiagnosed entity. Neurology. 2003;61:316–21.
   PubMed Web of Science ®Google Scholar
• Lundberg IE, Tjarnlund A, Bottai M, Werth VP, Pilkington C, Visser M, et al. 2017 European League against rheumatism/American College of Rheumatology Classification Criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76:1955–64.
   PubMed Web of Science ®Google Scholar
• van de Vlekkert J, Hoogendijk JE, de Haan RJ, Algra A, van der Tweel I, van der Pol WL, et al. Oral dexamethasone pulse therapy versus daily prednisolone in sub-acute onset myositis, a randomised clinical trial. Neuromuscul Disord. 2010;20:382–9.
   PubMed Web of Science ®Google Scholar
• Bunch TW. Prednisone and azathioprine for polymyositis: long-term followup. Arthritis Rheum. 1981;24:45–8.
   PubMed Web of Science ®Google Scholar
• Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92:365–9.
   PubMed Web of Science ®Google Scholar
• Cherin P, Pelletier S, Teixeira A, Laforet P, Genereau T, Simon A, et al. Results and long-term followup of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum. 2002;46:467–74.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993–2000.
   PubMed Web of Science ®Google Scholar
• Ge Y, Zhou H, Shi J, Ye B, Peng Q, Lu X, et al. The efficacy of tacrolimus in patients with refractory dermatomyositis/polymyositis: a systematic review. Clin Rheumatol. 2015;34:2097–103.
   PubMed Web of Science ®Google Scholar
• Kurita T, Yasuda S, Oba K, Odani T, Kono M, Otomo K, et al. The efficacy of tacrolimus in patients with interstitial lung diseases complicated with polymyositis or dermatomyositis. Rheumatology (Oxford). 2015;54:39–44.
   PubMed Web of Science ®Google Scholar
• Majithia V, Harisdangkul V. Mycophenolate mofetil (cellcept): an alternative therapy for autoimmune inflammatory myopathy. Rheumatology (Oxford). 2005;44:386–9.
   PubMed Web of Science ®Google Scholar
• Mitsui T, Kuroda Y, Ueno S, Kaji R. The effects of fk506 on refractory inflammatory myopathies. Acta Neurol Belg. 2011;111:188–94.
   PubMed Web of Science ®Google Scholar
• Miyasaka N, Hara M, Koike T, Saito E, Yamada M, Tanaka Y. Effects of intravenous immunoglobulin therapy in Japanese patients with polymyositis and dermatomyositis resistant to corticosteroids: a randomized double-blind placebo-controlled trial. Mod Rheumatol. 2012;22:382–93.
   PubMed Web of Science ®Google Scholar
• Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res. 2010;62:1496–501.
   PubMed Web of Science ®Google Scholar
• Newman ED, Scott DW. The use of low-dose oral methotrexate in the treatment of polymyositis and dermatomyositis. J Clin Rheumatol. 1995;1:99–102.
   PubMedGoogle Scholar
• Rouster-Stevens KA, Morgan GA, Wang D, Pachman LM. Mycophenolate mofetil: a possible therapeutic agent for children with juvenile dermatomyositis. Arthritis Care Res. 2010;62:1446–51.
   PubMed Web of Science ®Google Scholar
• Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387:671–8.
   PubMed Web of Science ®Google Scholar
• Vencovsky J, Jarosova K, Machacek S, Studynkova J, Kafkova J, Bartunkova J, et al. Cyclosporine a versus methotrexate in the treatment of polymyositis and dermatomyositis. Scand J Rheumatol 2000;29:95–102.
   PubMed Web of Science ®Google Scholar
• Villalba L, Hicks JE, Adams EM, Sherman JB, Gourley MF, Leff RL, et al. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens. Arthritis Rheum. 1998;41:392–9.
   PubMed Web of Science ®Google Scholar
• Yamasaki Y, Yamada H, Yamasaki M, Ohkubo M, Azuma K, Matsuoka S, et al. Intravenous cyclophosphamide therapy for progressive interstitial pneumonia in patients with polymyositis/dermatomyositis. Rheumatology (Oxford). 2007;46:124–30.
   PubMed Web of Science ®Google Scholar
• Amato AA, Gronseth GS, Jackson CE, Wolfe GI, Katz JS, Bryan WW, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1996;40:581–6.
   PubMed Web of Science ®Google Scholar
• Ghirardello A, Bassi N, Palma L, Borella E, Domeneghetti M, Punzi L, et al. Autoantibodies in polymyositis and dermatomyositis. Curr Rheumatol Rep. 2013;15:335.
   PubMed Web of Science ®Google Scholar
• Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, et al. The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies. Medicine (Baltimore). 2013;92:223–43.
   PubMed Web of Science ®Google Scholar
• Hamaguchi Y, Kuwana M, Hoshino K, Hasegawa M, Kaji K, Matsushita T, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol. 2011;147:391–8.
   PubMedGoogle Scholar
• Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015;72:449–55.
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016;28:636–44.
   PubMed Web of Science ®Google Scholar
• Mammen AL, Chung T, Christopher-Stine L, Rosen P, Rosen A, Doering KR, et al. Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase in patients with statin-associated autoimmune myopathy. Arthritis Rheum. 2011;63:713–21.
   PubMed Web of Science ®Google Scholar
• Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med. 2016;280:8–23.
   PubMed Web of Science ®Google Scholar
• Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clinic Rev Allerg Immunol. 2017;52:1–19.
   PubMed Web of Science ®Google Scholar
• Amato AA, Barohn RJ. Evaluation and treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 2009;80:1060–8.
   PubMed Web of Science ®Google Scholar
• Layzer R, Lee HS, Iverson D, Margeta M. Dermatomyositis with inclusion body myositis pathology. Muscle Nerve. 2009;40:469–71.
   PubMed Web of Science ®Google Scholar
• Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol. 2001;28:1591–9.
   PubMed Web of Science ®Google Scholar
• Streib EW, Wilbourn AJ, Mitsumoto H. Spontaneous electrical muscle fiber activity in polymyositis and dermatomyositis. Muscle Nerve. 1979;2:14–8.
   PubMed Web of Science ®Google Scholar
• Wilbourn AJ. The electrodiagnostic examination with myopathies. J Clin Neurophysiol. 1993;10:132–48.
   PubMed Web of Science ®Google Scholar
• May DA, Disler DG, Jones EA, Balkissoon AA, Manaster BJ. Abnormal signal intensity in skeletal muscle at MR imaging: patterns, pearls, and pitfalls. Radiographics. 2000;20:S295–315.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Kurosaka D, Joh K, Matsushima S, Takahashi E, Hirai K, et al. Fasciitis as a common lesion of dermatomyositis, demonstrated early after disease onset by en bloc biopsy combined with magnetic resonance imaging. Arthritis Rheum. 2010;62:3751–9.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Nishioka M, Matsushima S, Joh K, Oto Y, Yoshiga M, et al. Brief report: power doppler ultrasonography for detection of increased vascularity in the fascia: a potential early diagnostic tool in fasciitis of dermatomyositis. Arthritis Rheumatol. 2016;68:2986–91.
   PubMed Web of Science ®Google Scholar
• Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP. Dermatomyositis: a clinicopathological study of 40 patients. Am J Dermatopathol. 2009;31:61–7.
   PubMed Web of Science ®Google Scholar
• Tjarnlund A, Tang Q, Wick C, Dastmalchi M, Mann H, Tomasova SJ, et al. Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase iib treatment delayed-start trial. Ann Rheum Dis. 2018;77:55–62.
   PubMed Web of Science ®Google Scholar
• Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-t-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology 2003;61(2):260.
   PubMed Web of Science ®Google Scholar
• Ibrahim F, Choy E, Gordon P, Dore CJ, Hakim A, Kitas G, et al. Second-line agents in myositis: 1-year factorial trial of additional immunosuppression in patients who have partially responded to steroids. Rheumatology (Oxford). 2015;54:1050–5.
   PubMed Web of Science ®Google Scholar
• Muscle SG. Randomized pilot trial of betainf1a (avonex) in patients with inclusion body myositis. Neurology 2001;57:1566–70.
   PubMed Web of Science ®Google Scholar
• Muscle Study Group. Randomized pilot trial of high-dose betainf-1a in patients with inclusion body myositis. Neurology 2004;63:718–20.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of ibm. Neurology 2001;56:323–7.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with ivig: a double-blind, placebo-controlled study. Neurology 1997;48:712–6.
   PubMed Web of Science ®Google Scholar
• Walter MC, Lochmuller H, Toepfer M, Schlotter B, Reilich P, Schroder M, et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol. 2000;247:22–8.
   PubMed Web of Science ®Google Scholar
• Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51:369–72.
   PubMed Web of Science ®Google Scholar
• Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65:314–24.
   PubMed Web of Science ®Google Scholar
• Amato AA. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427–36.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Marder G, Koontz DC, Nandkumar P, Qi Z, Oddis CV. Efficacy and safety of adrenocorticotropic hormone gel in refractory dermatomyositis and polymyositis. Ann Rheum Dis. 2018;77:720–7.
   PubMed Web of Science ®Google Scholar
• Allenbach Y, Guiguet M, Rigolet A, Marie I, Hachulla E, Drouot L, et al. Efficacy of rituximab in refractory inflammatory myopathies associated with anti- synthetase auto-antibodies: an open-label, phase ii trial. PLoS One. 2015;10:e0133702.
   PubMed Web of Science ®Google Scholar
• Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol. 2007;143:763–7.
   PubMed Web of Science ®Google Scholar
• Dalakas MC, Rakocevic G, Schmidt J, Salajegheh M, McElroy B, Harris-Love MO, et al. Effect of alemtuzumab (campath 1-h) in patients with inclusion-body myositis. Brain. 2009;132:1536–44.
   PubMed Web of Science ®Google Scholar
• Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Helmers SB, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008;67:1670–7.
   PubMed Web of Science ®Google Scholar
• Gottfried I, Seeber A, Anegg B, Rieger A, Stingl G, Volc-Platzer B. High dose intravenous immunoglobulin (ivig) in dermatomyositis: clinical responses and effect on sil-2r levels. Eur J Dermatol. 2000;10:29–35.
   PubMed Web of Science ®Google Scholar
• Hengstman GJ, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN, et al. Open-label trial of anti-tnf-alpha in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol. 2008;59:159–63.
   PubMed Web of Science ®Google Scholar
• Kosmidis ML, Alexopoulos H, Tzioufas AG, Dalakas MC. The effect of anakinra, an il1 receptor antagonist, in patients with sporadic inclusion body myositis (sibm): a small pilot study. J Neurol Sci. 2013;334:123–5.
   PubMed Web of Science ®Google Scholar
• Saito E, Koike T, Hashimoto H, Miyasaka N, Ikeda Y, Hara M, et al. Efficacy of high-dose intravenous immunoglobulin therapy in japanese patients with steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2008;18:34–44.
   PubMed Web of Science ®Google Scholar
• Zong M, Dorph C, Dastmalchi M, Alexanderson H, Pieper J, Amoudruz P, et al. Anakinra treatment in patients with refractory inflammatory myopathies and possible predictive response biomarkers: a mechanistic study with 12 months follow-up. Ann Rheum Dis. 2014;73:913–20.
   PubMed Web of Science ®Google Scholar
• Hara M, Kinoshita M, Saito E, Hashimoto H, Miyasaka N, Yoshida T, et al. Prospective study of high-dose intravenous immunoglobulin for the treatment of steroid-resistant polymyositis and dermatomyositis. Mod Rheumatol. 2003;13:319–25.
   PubMedGoogle Scholar
• Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19:138–41.
   PubMed Web of Science ®Google Scholar
• Bader-Meunier B, Decaluwe H, Barnerias C, Gherardi R, Quartier P, Faye A, et al. Safety and efficacy of rituximab in severe juvenile dermatomyositis: results from 9 patients from the french autoimmunity and rituximab registry. J Rheumatol. 2011;38:1436–40.
   PubMed Web of Science ®Google Scholar
• Danieli MG, Moretti R, Gambini S, Paolini L, Gabrielli A. Open-label study on treatment with 20% subcutaneous igg administration in polymyositis and dermatomyositis. Clin Rheumatol. 2014;33:531–6.
   PubMed Web of Science ®Google Scholar
• Garcia Hernandez FJ, Chinchilla Palomares E, Castillo Palma MJ, Gonzalez Pulido C, Ocana Medina C, Sanchez RJ. [Evaluation of the effectiveness of treatment with rituximab associated to cyclophosphamide in patients with resistant idiopathic inflammatory myopathy]. Med Clin (Barc) 2010;135:256–9.
   PubMed Web of Science ®Google Scholar
• Matsubara S, Kondo K, Sugaya K, Miyamoto K. Effects of tacrolimus on dermatomyositis and polymyositis: a prospective, open, non-randomized study of nine patients and a review of the literature. Clin Rheumatol. 2012;31:1493–8.
   PubMed Web of Science ®Google Scholar
• Matsubara S, Sawa Y, Takamori M, Yokoyama H, Kida H. Pulsed intravenous methylprednisolone combined with oral steroids as the initial treatment of inflammatory myopathies. J Neurol Neurosurg Psychiatry. 1994;57:1008.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, To CH. Rituximab for refractory polymyositis: an open-label prospective study. Torj. 2007;34:1864–8.
   Google Scholar
• Rouster-Stevens KA, Ferguson L, Morgan G, Huang CC, Pachman LM. Pilot study of etanercept in patients with refractory juvenile dermatomyositis. Arthritis Care Res (Hoboken). 2014;66:783–7.
   PubMed Web of Science ®Google Scholar
• Barohn RJ, Herbelin L, Kissel JT, King W, McVey AL, Saperstein DS, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology 2006;66:S123–S4.
   PubMed Web of Science ®Google Scholar
• Nagasaka K, Harigai M, Tateishi M, Hara M, Yoshizawa Y, Koike T, et al. Efficacy of combination treatment with cyclosporin a and corticosteroids for acute interstitial pneumonitis associated with dermatomyositis. Mod Rheumatol. 2003;13:231–8.
   PubMedGoogle Scholar
• Kotani T, Makino S, Takeuchi T, Kagitani M, Shoda T, Hata A, et al. Early intervention with corticosteroids and cyclosporin a and 2-hour postdose blood concentration monitoring improves the prognosis of acute/subacute interstitial pneumonia in dermatomyositis. J Rheumatol. 2008;35:254–9.
   PubMed Web of Science ®Google Scholar
• Lam CG, Manlhiot C, Pullenayegum EM, Feldman BM. Efficacy of intravenous ig therapy in juvenile dermatomyositis. Ann Rheum Dis. 2011;70:2089–94.
   PubMed Web of Science ®Google Scholar
• Dobloug C, Walle-Hansen R, Gran JT, Molberg O. Long-term follow-up of sporadic inclusion body myositis treated with intravenous immunoglobulin: a retrospective study of 16 patients. Clin Exp Rheumatol. 2012;30:838–42.
   PubMed Web of Science ®Google Scholar
• Kampylafka EI, Kosmidis ML, Panagiotakos DB, Dalakas M, Moutsopoulos HM, Tzioufas AG. The effect of intravenous immunoglobulin (ivig) treatment on patients with dermatomyositis: a 4-year follow-up study. Clin Exp Rheumatol. 2012;30:397–401.
   PubMed Web of Science ®Google Scholar
• Nzeusseu A, Brion F, Lefebvre C, Knoops P, Devogelaer JP, Houssiau FA. Functional outcome of myositis patients: Can a low-dose glucocorticoid regimen achieve good functional results?. Clin Exp Rheumatol. 1999;17:441–6.
   PubMed Web of Science ®Google Scholar
• Seshadri R, Feldman BM, Ilowite N, Cawkwell G, Pachman LM. The role of aggressive corticosteroid therapy in patients with juvenile dermatomyositis: a propensity score analysis. Arthritis Rheum. 2008;59:989–95.
   PubMed Web of Science ®Google Scholar
• Yanagisawa T, Sueishi M, Nawata Y, Akimoto T, Nozaki T, Koike T, et al. Methylprednisolone pulse therapy in dermatomyositis. Dermatologica 1983;167:47–51.
   PubMedGoogle Scholar
• Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52:3570–8.
   PubMed Web of Science ®Google Scholar
• Joffe MM, Love LA, Leff RL, Fraser DD, Targoff IN, Hicks JE, et al. Drug therapy of the idiopathic inflammatory myopathies: Predictors of response to prednisone, azathioprine, and methotrexate and a comparison of their efficacy. Am J Med. 1993;94:379–87.
   PubMed Web of Science ®Google Scholar
• Uchino M, Yamashita S, Uchino K, Hara A, Koide T, Suga T, et al. Long-term outcome of polymyositis treated with high single-dose alternate-day prednisolone therapy. Eur Neurol. 2012;68:117–21.
   PubMed Web of Science ®Google Scholar
• Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, et al. Rituximab in the treatment of jo1 antibody-associated antisynthetase syndrome: anti-ro52 positivity as a marker for severity and treatment response. J Rheumatol. 2016;43:1566–74.
   PubMed Web of Science ®Google Scholar
• Ueno KI, Shimojima Y, Kishida D, Sekijima Y, Ikeda SI. Advantage of administering tacrolimus for improving prognosis of patients with polymyositis and dermatomyositis. Int J Rheum Dis. 2016;19:1322–30.
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Furuta S, Ikeda K, Hirose K, Nakajima H. Corticosteroid-sparing effect of tacrolimus in the initial treatment of dermatomyositis and polymyositis. Mod Rheumatol. 2015;25:888–92.
   PubMed Web of Science ®Google Scholar
• Takada K, Kishi J, Miyasaka N. Step-up versus primary intensive approach to the treatment of interstitial pneumonia associated with dermatomyositis/polymyositis: a retrospective study. Mod Rheumatol. 2007;17:123–30.
   PubMedGoogle Scholar
• Go DJ, Park JK, Kang EH, Kwon HM, Lee YJ, Song YW, et al. Survival benefit associated with early cyclosporine treatment for dermatomyositis-associated interstitial lung disease. Rheumatol Int. 2016;36:125–31.
   PubMed Web of Science ®Google Scholar
• Levine T. Treating refractory dermatomyositis or polymyositis with adrenocorticotropic hormone gel: A retrospective case series. Drug Des Devel Ther. 2012;6:133–9.
   PubMed Web of Science ®Google Scholar
• Reiff A, Rawlings DJ, Shaham B, Franke E, Richardson L, Szer IS, et al. Preliminary evidence for cyclosporin a as an alternative in the treatment of recalcitrant juvenile rheumatoid arthritis and juvenile dermatomyositis. J Rheumatol. 1997;24:2436–43.
   PubMed Web of Science ®Google Scholar
• Cavagna L, Caporali R, Abdi-Ali L, Dore R, Meloni F, Montecucco C. Cyclosporine in anti-jo1-positive patients with corticosteroid-refractory interstitial lung disease. J Rheumatol. 2013;40:484–92.
   PubMed Web of Science ®Google Scholar
• Miyake S, Ohtani Y, Sawada M, Inase N, Miyazaki Y, Takano S, et al. Usefulness of cyclosporine a on rapidly progressive interstitial pneumonia in dermatomyositis. Sarcoidosis Vasc Diffuse Lung Dis. 2002;19:128–33.
   PubMed Web of Science ®Google Scholar
• Zeller V, Cohen P, Prieur AM, Guillevin L. Cyclosporin a therapy in refractory juvenile dermatomyositis. Experience and longterm followup of 6 cases. J Rheumatol. 1996;23:1424–7.
   PubMed Web of Science ®Google Scholar
• Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology (Oxford). 2004;43:491–6.
   PubMed Web of Science ®Google Scholar
• Al-Mayouf SM, Laxer RM, Schneider R, Silverman ED, Feldman BM. Intravenous immunoglobulin therapy for juvenile dermatomyositis: efficacy and safety. J Rheumatol. 2000;27:2498–503.
   PubMed Web of Science ®Google Scholar
• Cherin P, Belizna C, Cartry O, Lascu-Dubos G, de Jaeger C, Delain JC, et al. Long-term subcutaneous immunoglobulin use in inflammatory myopathies: a retrospective review of 19 cases. Autoimmun Rev. 2016;15:281–6.
   PubMed Web of Science ®Google Scholar
• Marie I, Menard JF, Hatron PY, Hachulla E, Mouthon L, Tiev K, et al. Intravenous immunoglobulins for steroid-refractory esophageal involvement related to polymyositis and dermatomyositis: a series of 73 patients. Arthritis Care Res. 2010;62:1748–55.
   PubMed Web of Science ®Google Scholar
• Speth F, Haas JP, Hinze CH. Treatment with high-dose recombinant human hyaluronidase-facilitated subcutaneous immune globulins in patients with juvenile dermatomyositis who are intolerant to intravenous immune globulins: a report of 5 cases. Pediatr Rheumatol. 2016;14:52.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Hayakawa H, Miwa S, Shirai M, Fujii M, Gemma H, et al. Intravenous immunoglobulin therapy for refractory interstitial lung disease associated with polymyositis/dermatomyositis. Lung. 2009;187:201–6.
   PubMed Web of Science ®Google Scholar
• Dagher R, Desjonqueres M, Duquesne A, Quartier P, Bader-Meunier B, Fischbach M, et al. Mycophenolate mofetil in juvenile dermatomyositis: a case series. Rheumatol Int. 2012;32:711–6.
   PubMed Web of Science ®Google Scholar
• Pisoni CN, Cuadrado MJ, Khamashta MA, Hughes GR, D'Cruz DP. Mycophenolate mofetil treatment in resistant myositis. Rheumatology (Oxford). 2007;46:516–8.
   PubMed Web of Science ®Google Scholar
• Raghu P, Manadan AM, Schmukler J, Mathur T, Block JA. Pulse dose methylprednisolone therapy for adult idiopathic inflammatory myopathy. Am J Ther. 2015;22:244–7.
   PubMed Web of Science ®Google Scholar
• Miller LC, Sisson BA, Tucker LB, DeNardo BA, Schaller JG. Methotrexate treatment of recalcitrant childhood dermatomyositis. Arthritis Rheum. 1992;35:1143–9.
   PubMed Web of Science ®Google Scholar
• Zieglschmid-Adams ME, Pandya AG, Cohen SB, Sontheimer RD. Treatment of dermatomyositis with methotrexate. J Am Acad Dermatol. 1995;32:754–7.
   PubMed Web of Science ®Google Scholar
• Mathur T, Manadan AM, Thiagarajan S, Hota B, Block JA. Corticosteroid monotherapy is usually insufficient treatment for idiopathic inflammatory myopathy. Am J Ther. 2015;22:350–4.
   PubMed Web of Science ®Google Scholar
• Andersson H, Sem M, Lund MB, Aalokken TM, Gunther A, Walle-Hansen R, et al. Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease. Rheumatology (Oxford). 2015;54:1420–8.
   PubMed Web of Science ®Google Scholar
• Sem M, Molberg O, Lund MB, Gran JT. Rituximab treatment of the anti-synthetase syndrome: A retrospective case series. Rheumatology (Oxford). 2009;48:968–71.
   PubMed Web of Science ®Google Scholar
• Sharp C, McCabe M, Dodds N, Edey A, Mayers L, Adamali H, et al. Rituximab in autoimmune connective tissue disease-associated interstitial lung disease. Rheumatology (Oxford). 2016;55:1318–24.
   PubMed Web of Science ®Google Scholar
• Basnayake C, Cash K, Blumbergs P, Limaye V. Use of rituximab in histologically confirmed idiopathic inflammatory myositis: a case series. Clin Rheumatol. 2015;34:371–7.
   PubMed Web of Science ®Google Scholar
• Kuye IO, Smith GP. The use of rituximab in the management of refractory dermatomyositis. J Drugs Dermatol. 2017;16:162–6.
   PubMed Web of Science ®Google Scholar
• Majmudar S, Hall HA, Zimmermann B. Treatment of adult inflammatory myositis with rituximab: An emerging therapy for refractory patients. J Clin Rheumatol. 2009;15:338–40.
   PubMed Web of Science ®Google Scholar
• Munoz-Beamud F, Isenberg DA. Rituximab as an effective alternative therapy in refractory idiopathic inflammatory myopathies. Clin Exp Rheumatol. 2013;31:896–903.
   PubMed Web of Science ®Google Scholar
• Unger L, Kampf S, Luthke K, Aringer M. Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population. Rheumatology (Oxford). 2014;53:1630–8.
   PubMed Web of Science ®Google Scholar
• Valiyil R, Casciola-Rosen L, Hong G, Mammen A, Christopher-Stine L. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series. Arthritis Care Res. 2010;62:1328–34.
   PubMed Web of Science ®Google Scholar
• Kurita T, Yasuda S, Amengual O, Atsumi T. The efficacy of calcineurin inhibitors for the treatment of interstitial lung disease associated with polymyositis/dermatomyositis. Lupus 2015;24:3–9.
   PubMed Web of Science ®Google Scholar
• Labirua-Iturburu A, Selva-O’Callaghan A, Martinez-Gomez X, Trallero-Araguas E, Labrador-Horrillo M, Vilardell-Tarres M. Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease. Clin Exp Rheumatol. 2013;31:436–9.
   PubMed Web of Science ®Google Scholar
• Sharma N, Putman MS, Vij R, Strek ME, Dua A. Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a us cohort. J Rheumatol. 2017;44:1612–8.
   PubMed Web of Science ®Google Scholar
• Shimojima Y, Ishii W, Matsuda M, Tazawa K, Ikeda S. Coadministration of tacrolimus with corticosteroid accelerates recovery in refractory patients with polymyositis/dermatomyositis: a retrospective study. BMC Musculoskelet Disord. 2012;13:228.
   PubMed Web of Science ®Google Scholar
• Takada K, Nagasaka K, Miyasaka N. Polymyositis/dermatomyositis and interstitial lung disease: a new therapeutic approach with t-cell-specific immunosuppressants. Autoimmunity 2005;38:383–92.
   PubMed Web of Science ®Google Scholar
• Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52:2439–46.
   PubMed Web of Science ®Google Scholar
• Witt LJ, Demchuk C, Curran JJ, Strek ME. Benefit of adjunctive tacrolimus in connective tissue disease-interstitial lung disease. Pulm Pharmacol Ther. 2016;36:46–52.
   PubMed Web of Science ®Google Scholar
• Chen D, Wang XB, Zhou Y, Zhu XC. Efficacy of infliximab in the treatment for dermatomyositis with acute interstitial pneumonia: a study of fourteen cases and literature review. Rheumatol Int. 2013;33:2455–8.
   PubMed Web of Science ®Google Scholar
• Efthimiou P, Schwartzman S, Kagen LJ. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006;65:1233–6.
   PubMed Web of Science ®Google Scholar
• Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G. Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol. 2006;33:1802–4.
   PubMed Web of Science ®Google Scholar
• Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin a, and intravenous pulse cyclophosphamide for acute/subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005;32:1719–26.
   PubMed Web of Science ®Google Scholar
• Sansome A, Dubowitz V. Intravenous immunoglobulin in juvenile dermatomyositis–four year review of nine cases. Arch Dis Child.1995;72:25–8.
   PubMed Web of Science ®Google Scholar
• Rider LG, Giannini EH, Brunner HI, Ruperto N, James-Newton L, Reed AM, et al. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum. 2004;50:2281–90.
   PubMed Web of Science ®Google Scholar
• Aggarwal R, Bandos A, Reed AM, Ascherman DP, Barohn RJ, Feldman BM, et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheumatol. 2014;66:740–9.
   PubMed Web of Science ®Google Scholar
• Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, et al. Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med. 2015;162:18–26.
   PubMed Web of Science ®Google Scholar